COMMUNIQUÉS West-GlobeNewswire

Tetra Bio-Pharma Confirms Agreements With Multiple Suppliers

11/12/2018 - 12:30

Quality and volume of Active Pharmaceutical Ingredients (API) ensured ORLEANS, Ontario, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“ Tetra ” or “ TBP ”), (TSX VENTURE: TBP) (OTCQB: TBPMF) a leader in [...]

Santhera's Extraordinary General Meeting Approves Capital Increase

11/12/2018 - 12:25

Pratteln, Switzerland, December 11, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces that a vast majority of shareholders approved the ordinary capital increase at today's Extraordinary General Meeting (EGM). [...]

Farmako: Cannabis distributor to become gateway to Europe

11/12/2018 - 10:00

Company is first to apply for a licence in the United Kingdom AAA-Team pushes to become gateway to Europe Company first to apply for distribution licences in UK Support of Canadian LP to obtain EU-GMP Focus on research [...]

A new scientific publication from AroCell confirming the value of AroCell TK 210 ELISA as a tool in drug discovery and development

11/12/2018 - 08:30

A peer-reviewed article has been published in the journal Nucleosides, Nucleotides and Nucleic Acids, entitled “Doxorubicin effects on leukemia and breast cancer cells in culture on the Thymidine Kinase 1 protein levels [...]

Rule 2.9 Announcement

11/12/2018 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 11 December 2018 [...]

Neovacs and Centurion Pharma continue their collaboration in Lupus based on the results of the Phase IIb trial with IFNalpha Kinoid

11/12/2018 - 07:31

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs and Centurion Pharma continue their collaboration in Lupus based on the results of the Phase IIb trial with IFNalpha Kinoid Paris and Boston, December 11 th 2018 - 7 [...]

Néovacs et Centurion Pharma poursuivent leur coopération en lupus suite aux résultats de l'étude de phase IIb avec l'IFNalpha Kinoide

11/12/2018 - 07:31

COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE NÉOVACS ET CENTURION PHARMA POURSUIVENT LEUR COOPÉRATION EN LUPUS SUITE AUX RÉSULTATS DE L'ÉTUDE DE PHASE IIB AVEC L'IFNalpha KINOIDE Paris et Boston, [...]

Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofipôle SA

11/12/2018 - 07:03

Regulated information Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings Gosselies, Belgium, 11 December 2018, 7am CET– BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone [...]

Bone Therapeutics SA : Notification de transparence reçue de la part de S.R.I.W. SA et Sofipôle SA

11/12/2018 - 07:03

Information réglementée Article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes Gosselies, Belgique, le 11 décembre, 7h00 CET - BONE THERAPEUTICS (code Euronext Bruxelles et [...]

Pascal Biosciences Announces Year-End Investor Update Webcast

11/12/2018 - 02:45

Advancement of Cannabinoid Cancer Programs and Corporate Review to be Presented Scheduled for Dec. 17, 2018 at 1:30 p.m. Pacific VANCOUVER, British Columbia and SEATTLE, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Pascal [...]

Golden Leaf Holdings announces change in Board of Director composition

11/12/2018 - 00:48

PORTLAND, Ore., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (“Golden Leaf” or the “Company”) (CSE:GLH) (OTCQB:GLDFF), a cannabis company with cultivation, production and retail operations built around [...]

CERESPIR INCORPORATED et le NATIONAL NEUROSCIENCE INSTITUTE – SINGAPOUR annoncent des données positives montrant les effets bénéfiques du composé Itanapraced de CERESPIR au stade clinique dans un modèle LRRK2 de la maladie de Parkinson

11/12/2018 - 00:15

Itanapraced bloque l'expression de LRRK2 et la neurotoxicité à médiation par LRRK2 Itanapraced est prêt à passer à la Phase 2 chez les patients atteints de la maladie de Parkinson avec ou sans mutation génétique NEW [...]

Wright Medical Group N.V. Announces Payment Date and Record Date for CVR Product Sales Milestone Payment

11/12/2018 - 00:00

AMSTERDAM, The Netherlands, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Wright Medical Group N.V. (NASDAQ:WMGI) today announced a contingent value right (CVR) milestone payment of US $1.50 per contingent value right (CVR) payable [...]

BELLUS Health Announces Overnight Marketed Equity Offering

10/12/2018 - 23:01

Not for Distribution to United States Newswire Services or for Dissemination in the United States LAVAL, Quebec, Dec. 10, 2018 (GLOBE NEWSWIRE) -- BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a [...]

BELLUS Santé annonce un placement d’actions ordinaires négocié entre deux séances boursières

10/12/2018 - 23:01

Ne pas distribuer aux agences de transmission américaines ni diffuser aux États-Unis LAVAL, Québec, 10 déc. 2018 (GLOBE NEWSWIRE) -- BELLUS Santé inc. (TSX : BLU) (« BELLUS Santé » ou la « société »), une société [...]

National Research Corporation Declares Special and Quarterly Dividend

10/12/2018 - 23:00

Lincoln, Nebraska, Dec. 10, 2018 (GLOBE NEWSWIRE) -- image002 National Research Corporation (NASDAQ:NRC) today announced that its Board of Directors has declared a special dividend of fifty cents ($0.50) per share to [...]

John M. Dineen Appointed to Syneos Health Board of Directors, Named Chairman

10/12/2018 - 23:00

MORRISVILLE, N.C., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that John M. Dineen has been appointed to the [...]

Constellation Pharmaceuticals Initiates Phase 2 Portion of ProSTAR Clinical Trial in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

10/12/2018 - 22:49

Dosing has begun in a randomized study of CPI-1205 / enzalutamide combination versus enzalutamide alone in second-line mCRPC Single-arm CPI-1205 / abiraterone / prednisone combination added to potentially address low [...]

MRI Interventions Congratulates Voyager Therapeutics on First Patient Dosing in RESTORE-1, the Phase 2 VY-AADC Gene Therapy Trial for Parkinson’s Disease

10/12/2018 - 22:42

IRVINE, Calif. , Dec. 10, 2018 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC), a platform neurosurgery company with products designed for navigation, ablation and gene therapy, today announced participation in [...]